Table 3.
Pretreatment and posttreatment clinical characteristics of type 2 diabetes patients with hypertriglyceridemia treated with fenofibrate.
| Parameters | Pretreatment (N = 25) |
Posttreatment (N = 25) |
P value |
|---|---|---|---|
| BMI (kg/m2) | 26.46 ± 4.60 | 26.37 ± 4.59 | 0.209 |
| SBP (mmHg) | 125.00 ± 7.56 | 125.48 ± 6.76 | 0.668 |
| DBP (mmHg) | 74.24 ± 8.74 | 73.92 ± 7.30 | 0.831 |
| FBG (mmol/L) | 7.42 ± 1.01 | 7.32 ± 1.00 | 0.215 |
| TC (mmol/L) | 4.62 ± 0.66 | 4.83 ± 0.69 | 0.145 |
| HDL (mmol/L) | 1.25 ± 0.29 | 1.47 ± 0.27 | <0.001 |
| LDL (mmol/L) | 2.80 ± 0.53 | 2.82 ± 0.66 | 0.845 |
| TG (mmol/L) | 3.05 ± 0.86 | 1.84 ± 0.76 | <0.001 |
| AST (U/L) | 22.08 ± 7.33 | 23.84 ± 9.04 | 0.322 |
| ALT (U/L) | 26.00 ± 5.69 | 24.44 ± 11.64 | 0.518 |
| CR (μmol/L) | 71.92 ± 13.74 | 76.10 ± 17.29 | 0.164 |
| CK (U/L) | 84.64 ± 27.69 | 91.20 ± 37.28 | 0.307 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CR, creatinine; CK, creatine kinase.